Targeting the Fas/FasL signaling pathway in cancer therapy

Bibliography

• Oehm A, Behrmann I, Falk W, Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267:10709-15
   PubMed Web of Science ®Google Scholar
• Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993;268:10932-7
   PubMed Web of Science ®Google Scholar
• Fas (TNF receptor superfamily, member 6). Available from: http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000026103;r=10:90729553-90775542 [Last accessed 6 October 2011]
   Google Scholar
• Cheng J, Zhou T, Liu C, Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tanaka M, Brannan CI, Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76
   PubMed Web of Science ®Google Scholar
• Fas ligand (TNF superfamily, member 6). Available from: http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117560;r=1:172628154-172636014 [Last accessed 6 October 2011]
   Google Scholar
• Kayagaki N, Kawasaki A, Ebata T, Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Yu WH, Poulaki V, Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001;61:577-81
   PubMed Web of Science ®Google Scholar
• Ehrenschwender M, Wajant H. The role of FasL and Fas in health and disease. Adv Exp Med Biol 2009;647:64-93
   Google Scholar
• Papoff G, Hausler P, Eramo A, Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 1999;274:38241-50
   PubMedGoogle Scholar
• Algeciras-Schimnich A, Shen L, Barnhart BC, Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 2002;22:207-20
   PubMed Web of Science ®Google Scholar
• Muzio M, Chinnaiyan AM, Kischkel FC, FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death–inducing signaling complex. Cell 1996;85:817-27
   PubMed Web of Science ®Google Scholar
• Medema JP, Scaffidi C, Kischkel FC, FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997;16:2794-804
   PubMed Web of Science ®Google Scholar
• Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-95
   PubMed Web of Science ®Google Scholar
• Lee HO, Ferguson TA. Biology of FasL. Cytokine Growth Factor Rev 2003;14:325-35
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
   PubMed Web of Science ®Google Scholar
• Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78:312-25
   PubMed Web of Science ®Google Scholar
• Villa-Morales M, Santos J, Perez-Gomez E, A role for the Fas/FasL system in modulating genetic susceptibility to T-cell lymphoblastic lymphomas. Cancer Res 2007;67:5107-16
   Google Scholar
• Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res 2006;130:141-65
   PubMedGoogle Scholar
• Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007;220:82-101
   PubMedGoogle Scholar
• Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008;8:74-80
   PubMed Web of Science ®Google Scholar
• Inaba H, Komada Y, Li QS, mRNA expression of variant Fas molecules in acute leukemia cells. Am J Hematol 1999;62:150-8
   PubMed Web of Science ®Google Scholar
• Tawara M, Maeda T, Yamada Y, Aberrant processing of Fas transcripts in adult T-cell leukemia: a possible role in tumor cell survival. Cancer Lett 2003;193:235-42
   Google Scholar
• van Doorn R, Dijkman R, Vermeer MH, A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 2002;62:5389-92
   Google Scholar
• Mullauer L, Gruber P, Sebinger D, Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 2001;488:211-31
   PubMed Web of Science ®Google Scholar
• Villa-Morales M, Gonzalez-Gugel E, Shahbazi MN, Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility. Carcinogenesis 2010;31:2165-71
   PubMed Web of Science ®Google Scholar
• Wu J, Siddiqui J, Nihal M, Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 2010;508:185-91
   Google Scholar
• Zhang B, Sun T, Xue L, Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28:1067-73
   PubMed Web of Science ®Google Scholar
• Gazin C, Wajapeyee N, Gobeil S, An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007;449:1073-7
   PubMed Web of Science ®Google Scholar
• Jones CL, Wain EM, Chu CC, Downregulation of Fas gene expression in Sezary syndrome is associated with promoter hypermethylation. J Invest Dermatol 2010;130:1116-25
   PubMedGoogle Scholar
• Santourlidis S, Warskulat U, Florl AR, Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma. Mol Carcinog 2001;32:36-43
   Google Scholar
• Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002;2:139-48
   PubMed Web of Science ®Google Scholar
• Park SM, Peter ME. microRNAs and death receptors. Cytokine Growth Factor Rev 2008;19:303-11
   PubMed Web of Science ®Google Scholar
• Peshes-Yaloz N, Rosen D, Sondel PM, Up-regulation of Fas (CD95) expression in tumour cells in vivo. Immunology 2007;120:502-11
   Google Scholar
• Ivanov VN, Lopez Bergami P, Maulit G, FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003;23:3623-35
   PubMedGoogle Scholar
• Strand S, Vollmer P, van den Abeelen L, Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 2004;23:3732-6
   PubMed Web of Science ®Google Scholar
• Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 2011;81:838-47
   PubMed Web of Science ®Google Scholar
• Schattenberg JM, Schuchmann M, Galle PR. Cell death and hepatocarcinogenesis: dysregulation of apoptosis signaling pathways. J Gastroenterol Hepatol 2011;26(Suppl 1):213-19
   PubMedGoogle Scholar
• Tourneur L, Mistou S, Michiels FM, Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene 2003;22:2795-804
   PubMed Web of Science ®Google Scholar
• Fulda S, Kufer MU, Meyer E, Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-77
   PubMed Web of Science ®Google Scholar
• Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000;60:4315-19
   PubMed Web of Science ®Google Scholar
• Blomberg J, Ruuth K, Santos D, Lundgren E. Acquired resistance to Fas/CD95 ligation in U937 cells is associated with multiple molecular mechanisms. Anticancer Res 2008;28(2A):593-9
   Google Scholar
• Gimenez-Bonafe P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009;9:320-40
   PubMed Web of Science ®Google Scholar
• Irmler M, Thome M, Hahne M, Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5
   PubMed Web of Science ®Google Scholar
• Wang L, Azad N, Kongkaneramit L, The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol 2008;180:3072-80
   PubMed Web of Science ®Google Scholar
• Huerta S, Heinzerling JH, Anguiano-Hernandez YM, Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res 2007;142:184-94
   PubMed Web of Science ®Google Scholar
• Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev 2002;3:401-10
   Google Scholar
• Trauth BC, Klas C, Peters AM, Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5
   PubMed Web of Science ®Google Scholar
• Ogasawara J, Watanabe-Fukunaga R, Adachi M, Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9
   PubMed Web of Science ®Google Scholar
• Rensing-Ehl A, Frei K, Flury R, Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995;25:2253-8
   PubMed Web of Science ®Google Scholar
• Kim SH, Bianco N, Menon R, Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther 2006;13:289-300
   PubMed Web of Science ®Google Scholar
• Scholz M, Cinatl J. Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med Res Rev 2005;25:331-42
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Hirabayashi Y, Matsuzaki Y, In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int Immunol 1997;9:307-16
   Google Scholar
• Yoshida H, Watanabe K, Takahashi S, Ichikawa K. Protective effects of HFE7A, mouse anti-human/mouse Fas monoclonal antibody against acute and lethal hepatic injury induced by Jo2. Cytotechnology 2010;62:313-23
   Google Scholar
• Haruyama H, Ito S, Miyadai K, Humanization of the mouse anti-Fas antibody HFE7A and crystal structure of the humanized HFE7A Fab fragment. Biol Pharm Bull 2002;25:1537-45
   Google Scholar
• Nakayama J, Ogawa Y, Yoshigae Y, A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells. Int Immunol 2006;18:113-24
   Google Scholar
• Saito-Yabe M, Yoshigae Y, Takasaki W, Highly frequent anti-idiotype antibody in cynomolgus monkeys developed against mouse-derived regions of anti-Fas antibody humanized by complementarity determining region grafting. Br J Pharmacol 2009;158:548-57
   Google Scholar
• Jung G, Grosse-Hovest L, Krammer PH, Rammensee HG. Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res 2001;61:1846-8
   Google Scholar
• Herrmann T, Grosse-Hovest L, Otz T, Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008;68:1221-7
   PubMed Web of Science ®Google Scholar
• Schneider P, Holler N, Bodmer JL, Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-13
   PubMed Web of Science ®Google Scholar
• Aoki K, Kurooka M, Chen JJ, Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol 2001;2:333-7
   PubMedGoogle Scholar
• Holler N, Tardivel A, Kovacsovics-Bankowski M, Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003;23:1428-40
   PubMed Web of Science ®Google Scholar
• Krippner-Heidenreich A, Grunwald I, Zimmermann G, Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 2008;180:8176-83
   PubMed Web of Science ®Google Scholar
• Berg D, Lehne M, Muller N, Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007;14:2021-34
   PubMed Web of Science ®Google Scholar
• Greaney P, Nahimana A, Lagopoulos L, A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk Res 2006;30:415-26
   Google Scholar
• Rikhof B, van der Graaf WT, Meijer C, Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br J Cancer 2008;99:1600-6
   PubMed Web of Science ®Google Scholar
• Verbrugge I, Maas C, Heijkoop M, Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death Differ 2010;17:551-61
   Google Scholar
• Eisele G, Roth P, Hasenbach K, APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-oncol 2011;13:155-64
   PubMed Web of Science ®Google Scholar
• TopoTarget A/S. A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors. ClinicalTrials.gov 2007 Available from: http://clinicaltrials.gov/ct2/results?term=apo010 [Last accessed 6 October 2011]
   Google Scholar
• Scanlan MJ, Raj BK, Calvo B, Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994;91:5657-61
   PubMed Web of Science ®Google Scholar
• Samel D, Muller D, Gerspach J, Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J Biol Chem 2003;278:32077-82
   Google Scholar
• Bremer E, ten Cate B, Samplonius DF, CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 2006;107:2863-70
   PubMed Web of Science ®Google Scholar
• Bremer E, Abdulahad WH, de Bruyn M, Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling. Immunol Lett 2011;138:161-8
   Google Scholar
• Bremer E, ten Cate B, Samplonius DF, Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res 2008;68:597-604
   PubMed Web of Science ®Google Scholar
• Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-36
   PubMed Web of Science ®Google Scholar
• Orbach A, Rachmilewitz J, Parnas M, CTLA-4. FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals. J Immunol 2007;179:7287-94
   Google Scholar
• Assohou-Luty C, Gerspach J, Siegmund D, A CD40–CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med 2006;84:785-97
   Google Scholar
• Orbach A, Rachmilewitz J, Shani N, CD40.FasL and CTLA-4.FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling. Am J Pathol 2010;177:3159-68
   Google Scholar
• Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer therapy. Cancer Lett 2011 [Epub ahead of print] doi:10.1016/j.canlet.2010.12.019
   Google Scholar
• Watermann I, Gerspach J, Lehne M, Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ 2007;14:765-74
   PubMed Web of Science ®Google Scholar
• Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997;94:13862-7
   PubMed Web of Science ®Google Scholar
• Hedlund TE, Meech SJ, Srikanth S, Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 1999;6:175-82
   PubMed Web of Science ®Google Scholar
• Ambar BB, Frei K, Malipiero U, Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther 1999;10:1641-8
   PubMed Web of Science ®Google Scholar
• Candolfi M, Yagiz K, Foulad D, Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 2009;15:4401-14
   PubMed Web of Science ®Google Scholar
• Fecker LF, Schmude M, Jost S, Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus. Exp Dermatol 2010;19:e56-66
   Google Scholar
• Hyer ML, Sudarshan S, Schwartz DA, Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther 2003;10:330-9
   PubMedGoogle Scholar
• Kodaira H, Kume A, Ogasawara Y, Fas and mutant estrogen receptor chimeric gene: a novel suicide vector for tamoxifen-inducible apoptosis. Jpn J Cancer Res 1998;89:741-7
   Google Scholar
• Li X, Liu YH, Zhang YP, Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 2007;13:5463-73
   PubMedGoogle Scholar
• Morelli AE, Larregina AT, Smith-Arica J, Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol 1999;80:571-83
   PubMed Web of Science ®Google Scholar
• Norris JS, Bielawska A, Day T, Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther 2006;13:1045-51
   PubMed Web of Science ®Google Scholar
• Okuyama T, Fujino M, Li XK, Efficient Fas-ligand gene expression in rodent liver after intravenous injection of a recombinant adenovirus by the use of a Cre-mediated switching system. Gene Ther 1998;5:1047-53
   Google Scholar
• Aoki K, Akyurek LM, San H, Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol Ther 2000;1(6):555-65
   Google Scholar
• Rubinchik S, Wang D, Yu H, A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther 2001;4:416-26
   PubMed Web of Science ®Google Scholar
• Sipo I, Hurtado Pico A, Wang X, An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. J Mol Med 2006;84:215-25
   PubMed Web of Science ®Google Scholar
• Smith RC, Machluf M, Bromley P, Spatial and temporal control of transgene expression through ultrasound-mediated induction of the heat shock protein 70B promoter in vivo. Hum Gene Ther 2002;13:697-706
   Google Scholar
• Ho MY, Sun GH, Leu SJ, Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma. Int J Cancer 2008;123:123-33
   Google Scholar
• Ho IA, Ng WH, Lam PY. FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors. Mol Cancer 2010;9:270
   Google Scholar
• Symes JC, Siatskas C, Fowler DH, Medin JA. Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. Cancer Gene Ther 2009;16:439-52
   Google Scholar
• Bernardes N, Seruca R, Chakrabarty AM, Fialho AM. Microbial-based therapy of cancer: current progress and future prospects. Bioeng Bugs 2010;1:178-90
   PubMedGoogle Scholar
• Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Inhibition of tumor growth using Salmonella expressing Fas ligand. J Natl Cancer Inst 2008;100:1113-16
   PubMed Web of Science ®Google Scholar
• Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Exp Cell Res 2010;316:887-99
   PubMed Web of Science ®Google Scholar
• Raghavendra PB, Pathak N, Manna SK. Novel role of thiadiazolidine derivatives in inducing cell death through Myc-Max, Akt, FKHR, and FasL pathway. Biochem Pharmacol 2009;78:495-503
   Google Scholar
• Heikaus S, Matuszek KS, Suschek CV, Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L). J Cancer Res Clin Oncol 2008;134:689-95
   Google Scholar
• Volpert OV, Zaichuk T, Zhou W, Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results?term=ABT-510 [Last accessed 6 October 2011]
   Google Scholar
• Ebbinghaus S, Hussain M, Tannir N, Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007;13:6689-95
   Google Scholar
• Muller M, Wilder S, Bannasch D, p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188:2033-45
   PubMed Web of Science ®Google Scholar
• Amoroso A, Hafsi S, Militello L, Understanding rituximab function and resistance: implications for tailored therapy. Front Biosci 2011;16:770-82
   PubMed Web of Science ®Google Scholar
• Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 2010;23:189-96
   Google Scholar
• Almendro V, Ametller E, Garcia-Recio S, The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS One 2009;4:e4728
   Google Scholar
• Bousserouel S, Kauntz H, Gosse F, Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Int J Oncol 2010;36:1485-90
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results?term=ag3340 [Last accessed 6 October 2011]
   Google Scholar
• ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results?term=bisphosphonates&cond=cancer [Last accessed 6 October 2011]
   Google Scholar
• ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results?term=AE-941 [Last accessed 6 October 2011]
   Google Scholar
• Bissett D, O'Byrne KJ, von Pawel J, Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005;23:842-9
   PubMed Web of Science ®Google Scholar
• Heath EI, Burtness BA, Kleinberg L, Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs 2006;24:135-40
   PubMedGoogle Scholar
• Fizazi K, Lipton A, Mariette X, Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71
   PubMed Web of Science ®Google Scholar
• Lu C, Lee JJ, Komaki R, Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized Phase III trial. J Natl Cancer Inst 2010;102:859-65
   PubMed Web of Science ®Google Scholar
• Dorman G, Cseh S, Hajdu I, Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010;70:949-64
   PubMed Web of Science ®Google Scholar
• Ametller E, Garcia-Recio S, Pastor-Arroyo EM, Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death. Cancer Biol Ther 2011;11:4-13
   PubMed Web of Science ®Google Scholar
• Huang CR, Jin ZX, Dong L, Cisplatin augments FAS-mediated apoptosis through lipid rafts. Anticancer Res 2010;30:2065-71
   PubMedGoogle Scholar
• Rebillard A, Jouan-Lanhouet S, Jouan E, Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer 2010;46:1445-55
   PubMed Web of Science ®Google Scholar
• Mollinedo F, de la Iglesia-Vicente J, Gajate C, In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 2010;16:2046-54
   PubMed Web of Science ®Google Scholar
• Stel AJ, Ten Cate B, Jacobs S, Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol 2007;178:2287-95
   PubMed Web of Science ®Google Scholar
• Huang L, Ramirez JC, Frampton GA, Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest 2011;91:1007-17
   Google Scholar
• Lahiry L, Saha B, Chakraborty J, Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis 2010;31:259-68
   Web of Science ®Google Scholar
• Micheau O, Hammann A, Solary E, Dimanche-Boitrel MT. STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. Biochem Biophys Res Commun 1999;256:603-7
   PubMedGoogle Scholar
• Fulda S, Meyer E, Friesen C, Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 2001;20:1063-75
   PubMed Web of Science ®Google Scholar
• Bivona TG, Hieronymus H, Parker J, FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011;471:523-6
   PubMed Web of Science ®Google Scholar
• Duiker EW, van der Zee AG, de Graeff P, The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 2010;116:549-55
   PubMed Web of Science ®Google Scholar
• Tsumuraya T, Ishikawa C, Machijima Y, Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem Pharmacol 2011;81:713-22
   PubMed Web of Science ®Google Scholar
• Zhang G, Park MA, Mitchell C, Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 2008;14:5385-99
   PubMed Web of Science ®Google Scholar
• Pawar P, Ma L, Byon CH, Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res 2009;15:1288-96
   Google Scholar
• Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010;10:561-74
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Lopez-Chavez A, Citrin D, Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011;10:35
   PubMedGoogle Scholar
• Boumber Y, Issa JP. Epigenetics in cancer: what's the future? Oncology (Williston Park) 2011;25:220-6; 228
   PubMedGoogle Scholar
• van Noesel MM, van Bezouw S, Voute PA, Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 2003;38:226-33
   PubMed Web of Science ®Google Scholar
• Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011;147:443-9
   PubMedGoogle Scholar
• Poulaki V, Mitsiades CS, McMullan C, Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. Invest Ophthalmol Vis Sci 2005;46:358-66
   Google Scholar
• ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results?term=azacitidine [Last accessed 6 October 2011]
   Google Scholar
• ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results?term=decitabine [Last accessed 6 October 2011]
   Google Scholar
• Park MA, Mitchell C, Zhang G, Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca2+-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 2010;70:6313-24
   PubMed Web of Science ®Google Scholar
• Emanuele S, Lauricella M, Carlisi D, SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007;12:1327-38
   PubMed Web of Science ®Google Scholar
• Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007;6:2967-75
   PubMed Web of Science ®Google Scholar
• Murakami T, Sato A, Chun NA, Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 2008;128:1506-16
   Google Scholar
• Watanabe K, Okamoto K, Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 2005;12:10-18
   PubMed Web of Science ®Google Scholar
• Imai T, Adachi S, Nishijo K, FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 2003;22(58):9231-42
   Google Scholar
• Aron JL, Parthun MR, Marcucci G, Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003;102:652-8
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results?term=vorinostat [Last accessed 6 October 2011]
   Google Scholar
• ClinicalTrials.gov Available from: http://clinicaltrials.gov/ct2/results?term=romidepsin%2C+FR901228 [Last accessed 6 October 2011]
   Google Scholar
• Bouzar AB, Boxus M, Defoiche J, Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009;144:41-52
   PubMed Web of Science ®Google Scholar
• Lee WJ, Chen YR, Tseng TH. Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol Rep 2011;25:583-91
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Rao-Bindal K, Kleinerman ES. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 2011;117:3457-67
   PubMedGoogle Scholar
• Geng L, Zhu B, Dai BH, A let-7/Fas double-negative feedback loop regulates human colon carcinoma cells sensitivity to Fas-related apoptosis. Biochem Biophys Res Commun 2011;408:494-9
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Kim HW, Ashraf M, Haider H. Diazoxide potentiates mesenchymal stem cell survival via NF-kappaB-dependent miR-146a expression by targeting Fas. Am J Physiol 2010;299:H1077-82
   PubMed Web of Science ®Google Scholar
• Chhabra R, Adlakha YK, Hariharan M, Upregulation of miR-23a-27a-24-2 cluster induces caspase-dependent and -independent apoptosis in human embryonic kidney cells. PLoS One 2009;4:e5848
   PubMed Web of Science ®Google Scholar
• Sayed D, He M, Hong C, MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 2010;285:20281-90
   PubMed Web of Science ®Google Scholar
• Schickel R, Park SM, Murmann AE, Peter ME. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010;38:908-15
   PubMed Web of Science ®Google Scholar
• Liu Z, Liu R, Qiu J, Combination of human Fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response. Cell Mol Immunol 2009;6:167-74
   Google Scholar
• Villa-Morales M, Santos J, Fernandez-Piqueras J. Functional Fas (Cd95/Apo-1) promoter polymorphisms in inbred mouse strains exhibiting different susceptibility to gamma-radiation-induced thymic lymphoma. Oncogene 2006;25:2022-9
   Google Scholar
• Loeder S, Drensek A, Jeremias I, Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 2010;126:2216-28
   PubMed Web of Science ®Google Scholar
• Nabors LB, Fiveash JB, Markert JM, A Phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 2010;67:313-19
   PubMedGoogle Scholar
• Campbell NE, Greenaway J, Henkin J, The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 2010;12:275-83
   PubMed Web of Science ®Google Scholar